Search Patents
  • Lysosomal proteins produced in the milk of transgenic animals
    Patent number: 6118045
    Abstract: The invention provides transgenic nonhuman mammals producing phosphorylated lysosomal proteins in their milk, and methods of generating the same. Phosphorylation occurs at the 6' position of a mannose side chain residue. Also provided are methods of purifying lysosomal proteins from milk, and incorporating the proteins into pharmaceutical compositions for use in enzyme replacement therapy.
    Type: Grant
    Filed: July 29, 1996
    Date of Patent: September 12, 2000
    Assignees: Pharming B.V., The Universiteit Leiden, Academic Hospital, Eramus Universiteit
    Inventors: Arnold J. J. Reuser, Ans T. Van der Ploeg, Frank R. Pieper, Martin Ph. Verbeet
  • DNA sequences to target proteins to the mammary gland for efficient secretion
    Publication number: 20040266711
    Abstract: Described is a method of targeting specific genes to the mammary gland which results in the efficient synthesis and secretion of biologically important molecules. Further, there is described as a composition of matter, a transgenic mammal having the ability to reproduce itself and being suitable for the secretion of biologically active agents into its milk. Additionally there is disclosed as a composition of matter, recombinant DNA gene complexes designed to integrate into a mammalian genome and to synthesize and secrete biological active agents into the milk. Furthermore, methods of producing and using altered milk are disclosed.
    Type: Application
    Filed: March 3, 2004
    Publication date: December 30, 2004
    Applicant: Pharming B.V.
    Inventor: Jeffrey M. Rosen
  • Transgenic bovine
    Patent number: 5741957
    Abstract: A transgenic bovine is disclosed whose somatic and germ cells contain a transgene, wherein the transgene comprising a mammary gland specific promoter, a mammary gland specific enhancer, a DNA sequence encoding a signal sequence functional in bovine mammary gland secretory cells and a DNA sequence encoding a heterologous polypeptide of interest wherein the transgenic bovine expresses the transgene such that the polypeptide of interest is detectable in milk produced by the transgenic bovine.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: April 21, 1998
    Assignee: Pharming B.V.
    Inventors: Herman A. Deboer, Rein Strijker, Herbert L. Heyneker, Gerard Platenburg, Sang He Lee, Frank Pieper, Paul J. A. Krimpenfort
  • Fusion proteins incorporating lysozyme
    Patent number: 7045677
    Abstract: A process for the production of a peptide is disclosed, the process comprising expressing in the milk of a transgenic, non-human, placental mammal a fusion protein which comprises the peptide to be expressed linked to a fusion partner protein which is lysozyme. The fusion protein may be separate from the milk and cleaved to yield the target peptide. A transgenic, non-human, placental mammal whose genome incorporates a DNA molecule comprising a coding sequence encoding lysozyme coupled to a peptide is also described.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: May 16, 2006
    Assignee: Pharming Intellectual Property BV
    Inventors: Ian Robert Cottingham, Graham Edward McCreath
  • USING C1 ESTERASE INHIBITOR TO TREAT VIRAL INFECTION-RELATED ACUTE RESPIRATORY DISTRESS
    Publication number: 20210324107
    Abstract: The claimed invention relates to treatment of virus-related respiratory distress, particularly methods for treating such distress by administering a complement inhibitor. The types of virus-related respiratory distress that can be treated according to the invention include acute respiratory distress syndrome and related phenomena, and can be linked to infection by a coronavirus such as SARS-CoV-2. The invention includes administering complement inhibitor, which can be recombinant or purified Cl inhibitor, and administering complement inhibitor in combination with other therapeutics.
    Type: Application
    Filed: April 19, 2021
    Publication date: October 21, 2021
    Applicant: Pharming Intellectual Property B.V.
    Inventors: Bruno GIANNETTI, Jürgen SCHAALE, Anurag RELAN
  • Method for the production of biologically active polypeptides in a mammal's
    Patent number: 5959171
    Abstract: A process is disclosed for the production of a protein or polypeptide in the milk of a transgenic non-human mammal where the protein or polypeptide is produced as fusion protein with another protein. The fusion protein can then be cleaved to release the protein or polypeptide. This method would reduce or prevent the formation of side effects associated with ectopic expression or leakage of the protein or polypeptide. Such a fusion protein is .beta.-lactoglobulin-EPO, where biologically active EPO is released upon cleavage of the fusion protein.
    Type: Grant
    Filed: August 17, 1994
    Date of Patent: September 28, 1999
    Assignee: Pharming B.V.
    Inventors: Juha-Matti Hyttinen, Veli-Pekka Korhonen, Juhani Janne
  • DNA sequences to target proteins to the mammary gland for efficient secretion
    Patent number: 5565362
    Abstract: Described is a method of targeting specific genes to the mammary gland which results in the efficient synthesis and secretion of biologically important molecules. Further, there is described as a composition of matter, a transgenic mammal having the ability to reproduce itself and being suitable for the secretion of biologically active agents into its milk. Additionally there is disclosed as a composition of matter, recombinant DNA gene complexes designed to integrate into a mammalian genome and to synthesize and secrete biological active agents into the milk. Furthermore methods of producing and using altered milk are disclosed.
    Type: Grant
    Filed: January 24, 1994
    Date of Patent: October 15, 1996
    Assignee: Pharming B.V.
    Inventor: Jeffrey M. Rosen
  • Pesticides
    Patent number: 7442392
    Abstract: The invention provides the use of loquat kernel to kill, inactivate or repel pests, in particular nematodes. Also provided is a method of killing, inactivating or repelling nematodes, which method comprises providing loquat kernel and applying the loquat kernel to the nematodes or to an area where the nematodes are likely to exist or to an area to where the nematodes are expected to move. The invention further provides a pesticide comprising loquat kernel and a pesticidally acceptable solvent, carrier, excipient or diluent; and a method of producing a pesticide, which method comprises providing ground, chopped, freeze dried or spray dried loquat kernel.
    Type: Grant
    Filed: February 7, 2005
    Date of Patent: October 28, 2008
    Assignee: Pharming Ltd.
    Inventors: Ivo Baekelmans, Ron Herbert Brown, Irene Mueller-Harvey
  • Method of producing a transgenic bovine or transgenic bovine embryo
    Patent number: 5633076
    Abstract: A method is disclosed for the production of a transgenic bovine or a transgenic bovine embryo comprising obtaining an ovum from bovine ovaries, maturing the ovum in vitro, fertilizing the mature ovum or ova in vitro to form a zygote, introducing a transgene into the zygote in vitro and maturing the zygote to a preimplantation stage embryo in vitro. To produce the transgenic bovine, the embryo is transplanted into a recipient female bovine, wherein the female bovine gestates the embryo to produce a transgenic bovine.
    Type: Grant
    Filed: November 16, 1993
    Date of Patent: May 27, 1997
    Assignee: Pharming BV
    Inventors: Herman A. DeBoer, Rein Strijker, Herbert L. Heyneker, Gerard Platenburg, Sang H. Lee, Frank Pieper, Paul J. A. Krimpenfort
  • USING C1 ESTERASE INHIBITOR TO TREAT VIRAL INFECTION-RELATED ACUTE RESPIRATORY DISTRESS
    Publication number: 20230235023
    Abstract: The claimed invention relates to treatment of virus-related respiratory distress, particularly methods for treating such distress by administering a complement inhibitor. The types of virus-related respiratory distress that can be treated according to the invention include acute respiratory distress syndrome and related phenomena, and can be linked to infection by a coronavirus such as SARS-CoV-2. The invention includes administering complement inhibitor, which can be recombinant or purified C1 inhibitor, and administering complement inhibitor in combination with other therapeutics.
    Type: Application
    Filed: April 19, 2021
    Publication date: July 27, 2023
    Applicant: Pharming Intellectual Property B.V.
    Inventors: Bruno Giannetti, Anurag Relan, Juergen Ulrich Schaale-Maass
  • Purification of fibrinogen from fluids by precipitation and hydrophoic chromatography
    Patent number: 7211650
    Abstract: The present invention provides a method for the part purification of fibrinogen from milk, the method comprising the transfer of protease enzyme which is present in the milk, into the whey phase with the removal or partition if fibrinogen into another phase of the milk. The present invention also provides a method for obtaining fibrinogen from a fluid, the method comprising: a) contacting the fluid with a hydrophobic interaction chromatography resin under conditions where the fibrinogen binds to the resin; and b) removing the bound protein by means of elution.
    Type: Grant
    Filed: March 22, 2001
    Date of Patent: May 1, 2007
    Assignee: Pharming Intellectual Property BV
    Inventors: Graham McCreath, Udell Michael
  • Transgenic non human mammal milk
    Patent number: 5750172
    Abstract: This invention relates to the production of recombinant proteins, such as coagulation factors VIII and IX, tissue plasminogen activator (TPA), urokinase, growth hormone, insulin, interferons, interleukins, peptide hormones and immunoglobulins, in mammals' milk. Particularly, this invention relates to an expression system which when transgenically incorporated into a mammal permits the female species of that mammal to produce the desired recombinant protein in or along with its milk. This invention also relates to the transgenic mammal that produces the desired recombinant product in its milk.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: May 12, 1998
    Assignee: Pharming B.V.
    Inventors: Harry Meade, Nils Lonberg
  • Targeted synthesis of protein in mammary gland of a non-human transgenic mammal
    Patent number: 5994616
    Abstract: Described are methods of targeting specific genes or DNA sequences encoding biologically active proteins to the mammary gland such that the DNA sequence is expressed in the mammary gland and the protein is secreted into the milk of the mammal. Also described is the production of transgenic nonhuman mammals whose germ line comprises a DNA gene complex containing a casein promoter, a casein enhancer, a DNA sequence which encodes a signal peptide and a DNA sequence encoding a biologically active protein. The milk containing the biologically active protein or the biologically active protein itself can be used in the making of diary products.
    Type: Grant
    Filed: January 25, 1994
    Date of Patent: November 30, 1999
    Assignee: Pharming B.V.
    Inventor: Jeffrey M. Rosen
  • Production of human recombinant collagen in the milk of transgenic animals
    Patent number: 5895833
    Abstract: Production of human procollagen or collagen in cells which ordinarily do not produce these molecules is effected by constructing expression systems compatible with mammary glands of non-human mammals. For example, expression systems can be microinjected into fertilized oocytes and reimplanted in foster mothers and carried to term in order to obtain transgenic non-human mammals capable of producing milk containing recombinant human procollagen or collagen. Human procollagen or collagen produced in this manner can be made of a single collagen type uncontaminated by other human or non-human collagens.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 20, 1999
    Assignees: Cohesion Technologies, Inc., Pharming Holding NV
    Inventor: Richard A. Berg
  • Production of human recombinant collagen in the milk of transgenic animals
    Patent number: 6111165
    Abstract: Production of human procollagen or collagen in cells which ordinarily do not produce these molecules is effected by constructing expression systems compatible with mammary glands of non-human mammals. For example, expression systems can be microinjected into fertilized oocytes and reimplanted in foster mothers and carried to term in order to obtain transgenic non-human mammals capable of producing milk containing recombinant human procollagen or collagen. Human procollagen or collagen produced in this manner can be made of a single collagen type uncontaminated by other human or non-human collagens.
    Type: Grant
    Filed: January 15, 1999
    Date of Patent: August 29, 2000
    Assignees: Cohesion Technologies, Inc., Pharming BV
    Inventor: Richard A. Berg
  • Production of human recombinant collagen in the milk of transgenic mammals
    Patent number: 5962648
    Abstract: Production of human procollagen or collagen in cells which ordinarily do not produce these molecules is effected by constructing expression systems compatible with mammary glands of non-human mammals. For example, expression systems can be microinjected into fertilized oocytes and reimplanted in foster mothers and carried to term in order to obtain transgenic non-human mammals capable of producing milk containing recombinant human procollagen or collagen. Human procollagen or collagen produced in this manner can be made of a single collagen type uncontaminated by other human or non-human collagens.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 5, 1999
    Assignees: Cohesion Technologies, Inc., Pharming Holding NV
    Inventor: Richard A. Berg
  • Use of anticoagulants in the production of recombinant proteins in the milk of transgenic animals
    Patent number: 9546381
    Abstract: The invention relates to the production of recombinant human fibrinogen (rhFib) in the milk of transgenic mammalian animals. This production and subsequent purification process is generally hampered by the occurrence of so-called ‘clots’ and ‘flakes’ in the milk which, in severe cases, may prevent the cow from being milked at all, resulting in a halt of lactation. These clots and flakes occur because of the expression of the fibrinogen protein, which is a factor that is normally involved in blood clotting. The invention relates to solving this milk clotting problem by treating the (lactating) animals with anticoagulants such as coumarins. A preferred anticoagulant that is used in the methods of the present invention is warfarin.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: January 17, 2017
    Assignee: PHARMING INTELLECTUAL PROPERTY BV
    Inventors: Kathryn Margaret Nelson, Michael William Mosesson, Anthony Pusateri, Erik Jordahl Forsberg
  • Use of Anticoagulants in the Production of Recombinant Proteins in the Milk of Transgenic Animals
    Publication number: 20130053546
    Abstract: The invention relates to the production of recombinant human fibrinogen (rhFib) in the milk of transgenic mammalian animals. This production and subsequent purification process is generally hampered by the occurrence of so-called ‘clots’ and ‘flakes’ in the milk which, in severe cases, may prevent the cow from being milked at all, resulting in a halt of lactation. These clots and flakes occur because of the expression of the fibrinogen protein, which is a factor that is normally involved in blood clotting. The invention relates to solving this milk clotting problem by treating the (lactating) animals with anticoagulants such as coumarins. A preferred anticoagulant that is used in the methods of the present invention is warfarin.
    Type: Application
    Filed: March 11, 2011
    Publication date: February 28, 2013
    Applicant: PHARMING INTELLECTUAL PROPERTY BV
    Inventors: Kathryn Margaret Nelson, Michael William Mosesson, Anthony Pusateri, Erik Jordahl Forsberg
  • Method of controlling access to an internet-based application
    Patent number: 9628460
    Abstract: A novel method of dealing with the problem of phishing, pharming, key-logging and man-in-the-middle attacks on internet-based applications which require the submission of valid login credentials, by permitting a user to control access to an internet-based application (3) (such as an internet banking website) by the simple transmission of a command via the internet to allow access to the internet-based application (3) whenever the user wishes to access the application, and by transmitting a command via the internet to deny access to the internet-based application at all other times, to prevent unauthorized access by any unscrupulous parties.
    Type: Grant
    Filed: February 16, 2012
    Date of Patent: April 18, 2017
    Assignee: E-LOCK CORPORATION SDN. BHD.
    Inventors: Chik Weng Leong, Chee Hoo Lau, Yuen Len Kong, Tau Wei Phang, Hoon Sin Cheong
  • Production of fibrinogen in transgenic animals
    Patent number: RE42704
    Abstract: Materials and methods for producing fibrinogen in transgenic non-human mammals are disclosed. DNA segments encoding A?, B? and ? chains of fibrinogen are introduced into the germ line of a non-human mammal, and the mammal or its female progeny produces milk containing fibrinogen expressed from the introduced DNA segments. Non-human mammalian embryos and transgenic non-human mammals carrying DNA segments encoding heterologous fibrinogen polypeptide chains are also disclosed.
    Type: Grant
    Filed: January 15, 1999
    Date of Patent: September 13, 2011
    Assignee: Pharming Intellectual Property B.V.
    Inventors: Donna E. Prunkard, Donald C. Foster
Narrow Results

Filter by US Classification